Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

  1. Lucie Rodriguez
  2. Pirkka T. Pekkarinen
  3. Tadepally Lakshmikanth
  4. Ziyang Tan
  5. Camila Rosat Consiglio
  6. Christian Pou
  7. Yang Chen
  8. Constantin Habimana Mugabo
  9. Ngoc Anh Nguyen
  10. Kirsten Nowlan
  11. Tomas Strandin
  12. Lev Levanov
  13. Jaromir Mikes
  14. Jun Wang
  15. Anu Kantele
  16. Jussi Hepojoki
  17. Olli Vapalahti
  18. Santtu Heinonen
  19. Eliisa Kekäläinen
  20. Petter Brodin

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.xcrm.2020.100078
  2. ScreenIT

    SciScore for 10.1101/2020.06.03.20121582: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Detection of anti-SARS-CoV-2 antibody response: Antibodies against SARS-CoV-2 were measured using indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) using SARS-CoV-2 receptor-binding domain (RBD) as the antigen.
    SARS-CoV-2
    suggested: None
    SARS-CoV-2 receptor-binding domain (RBD
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    The RBD antigen was produced by transient transfection of RBD plasmid to Vero E6 cells and the produced protein was purified following established protocol (Stadlbauer et al., 2020).
    Vero E6
    suggested: None

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.03.20121582v2 on medRxiv
  4. Version published to 10.1101/2020.06.03.20121582v1 on medRxiv